(Q35205419)

7 August 2017

1 reference

title

Biosimilar medicines and cost-effectiveness (English)

1 reference

cost-effectiveness analysis

7 August 2017

main subject

1 reference

Steven Simoens

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

10 February 2011

1 reference

ClinicoEconomics and Outcomes Research

7 August 2017

published in

1 reference

7 August 2017

volume

3

1 reference

7 August 2017

page(s)

29-36

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

7 August 2017

copyright license

start time

1 February 2011

1 reference

April 2022 Public Data File from Crossref

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Pharmaceutical risk-sharing agreements

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

The challenge of biosimilars

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

The market for follow-on biologics: how will it evolve?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Review of NICE's recommendations, 1999-2005.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Defining and characterizing the late-stage biopharmaceutical pipeline

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Encouraging the use of generic medicines: implications for transition economies.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Health economic guidelines--similarities, differences and some implications

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Addressing the health technology assessment of biosimilar pharmaceuticals

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3169973

Biotechnology: the view from the FDA

26 September 2018

1 reference

12 December 2020

The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits

1 reference

12 December 2020

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

12 December 2020

Market access for biopharmaceuticals: new challenges

1 reference

12 December 2020

Do generics offer significant savings to the UK National Health Service?

1 reference

12 December 2020

What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems

1 reference

12 December 2020

Identifiers

DOI

10.2147/CEOR.S12494

1 reference

7 August 2017

1 reference

7 August 2017

1 reference